LiquidPiston Awarded Phase II Army Contract to Advance Hybrid Electrification for Unmanned Aerial Vehicles (UAVs)
September 13, 2022 09:00 ET
|
LiquidPiston
BLOOMFIELD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- LiquidPiston, Inc., the leading innovator of efficient engine technology and hybrid power systems, today announced a $1.7 million Phase II award...
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
January 18, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
Earth Science Tech, Inc. (ETST) Executes Phase I Acquisition of RxCompoundStore.com, LLC. and Peaks Curative, LLC.
November 04, 2021 09:00 ET
|
Earth Science Tech, Inc.
DORAL, FL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused in nutraceutical and pharmaceutical fields, and...
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
May 08, 2020 06:00 ET
|
Arch Biopartners
TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
January 27, 2020 01:30 ET
|
Deinove
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
November 14, 2019 13:22 ET
|
American BriVision Holding Corporation
PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no...
Pharmacovigilance Market will register 10.7% CAGR to cross $8.0 billion by 2024: Global Market Insights, Inc.
September 25, 2018 07:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Global Pharmacovigilance Market will surpass USD 8.0 billion by 2024; according to a new research report by Global Market Insights, Inc....
Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.
August 02, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be...
Pharmacovigilance Market will secure 10% CAGR to cross $8 billion by 2024: Global Market Insights, Inc.
March 19, 2018 07:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, March 19, 2018 (GLOBE NEWSWIRE) -- Global Pharmacovigilance Market is set to exceed USD 8 billion by 2024; according to a new research report by Global Market Insights....
Earth Science Tech, Inc. Signs Agreement with TransBiotech to start in Vitro & in Vivo in Phase II for Nutraceutical Patents
November 14, 2017 08:00 ET
|
Earth Science Tech, Inc.
Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp...